References
- Han T., Ezdinli E. Z., Shimaoka K., Desai D. V. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973; 31: 502–508
- Sawitsky A., Rai K. R., Glidewell O., Silver R. T., Participating members of CALGB (Cancer and Leukemia Group B). Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049–1059
- Kempin S., Lee I. B.J., II, Thaler H. T., Koziner B., Hecht S., Gee T., Arlin Z., Little C., Straus D., Reich L., Phillips E., Al-Mondhiry H., Dowling M., Mayer K., Clarkson B. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan and prednisone). Blood 1982; 60: 1110–1121
- Montserrat E., Alcala A., Parody R., Domingo A., Garcia-Conde J., Bueno J., Ferran C., Sanz M. A., Giralt M., Rubio D., Anton I., Estape J., Rozman C. Treatment of chronic lymphocytic leukemia in advanced stages-A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985; 56: 2369–2375
- Keller J. W., Knospe W. H., Raney M., Huguley C. M., Jr., Johnson L., Bartolucci A. A., Omura G. A. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy—A southwestern cancer study group trial. Cancer 1986; 58: 1185–1192
- Raphael B., Andersen J. W., Silber R., Oken M., Moore D., Bennett J., Bonner H., Hahn R., Knospe W. H., Mazza J., Glick J. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Longterm follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J. Clin. Oncol. 1991; 9: 770–776
- Keating M. J., Scouros M., Murphy S., Kantarjian H., Hester J., McCredie K. B., Hersh E. M., Freireich E. J. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157–164
- Keating M. J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Koller C., Beran M., Freireich E. J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–2884
- O'Brien S., Kantarjian H., Beran M., Smith T., Koller C., Estey E., Robertson L. E., Lerner S., Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood, in press
- Kemena A., O'Brien S., Kantarjian H., Robertson L., Koller C., Beran M., Estey E., Plunkett W., Lerner S., Keating M. J. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leukemia and Lymphoma 1993; 10: 187–193
- Robertson L. E., O'Brien S., Koller C., Beran M., Feldman E., Kantarjian H., Hagemeister F., Andreeff M., Lemer S., Plunkett W., Keating M. J. A three-day schedule of fludarabine in chronic lymphocytic leukemia (CLL). Proc. Am. Soc. Hematol. 1992; 80: 47a, Abstract
- Robertson L. E., Huh Y. O., Butler J. J., Pugh W. C., Hirsch-Ginsberg C., Stass S., Kantarjian H., Keating M. J. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80: 29–36
- Gribben J. G., Freedman A. S., Neuberg D., Roy D. C., Blake K. W., Woo S. D., Grossbard M. L., Coral F., Freeman G. J., Ritz J., Nadler L. M. Immunologic purging of polymerase chain reaction detectable lymphoma cells results in increased disease free survival following autologous bone marrow transplantation for B-cell non-Hodgkin's lymphomas. N. Engl. J. Med. 1991; 325: 1525